Ebenbuild Validates Lung Digital Twins in Nature Communications Medicine

Munich-based Ebenbuild GmbH has published a validation study in Nature Communications Medicine, confirming the strong predictive performance of its patient-specific lung digital twins. The peer-reviewed study demonstrates how the technology allows for highly accurate predictions of drug deposition in the lungs, a significant advancement in respiratory medicine and inhaled drug development. Using patient-specific anatomical data, the model addresses challenges such as individual lung anatomy and inhalation conditions.

The lung digital twin technology, validated against in vivo clinical imaging data using 3D SPECT/CT, aligns closely with measured outcomes, confirming its reliability. This capability enhances development decisions in pharmaceuticals by replacing assumptions with evidence.

Ebenbuild's platform applications, like TwinHale and AeroGram, leverage this technology for better drug delivery analysis and decision-support in intensive care. As the technology scales up, it supports a broader regulatory transition towards computational modeling in respiratory care.